166 related articles for article (PubMed ID: 21253919)
1. Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer.
Szarvas T; Jäger T; Becker M; Tschirdewahn S; Niedworok C; Kovalszky I; Rübben H; Ergün S; vom Dorp F
Pathol Oncol Res; 2011 Jun; 17(2):325-32. PubMed ID: 21253919
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer.
Szarvas T; Becker M; vom Dorp F; Gethmann C; Tötsch M; Bánkfalvi A; Schmid KW; Romics I; Rübben H; Ergün S
Cancer Sci; 2010 May; 101(5):1300-8. PubMed ID: 20180812
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
Szarvas T; Becker M; Vom Dorp F; Meschede J; Scherag A; Bánkfalvi A; Reis H; Schmid KW; Romics I; Rübben H; Ergün S
Int J Cancer; 2011 Mar; 128(6):1486-92. PubMed ID: 20473942
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival.
Yeh YC; Sheu BS; Cheng HC; Wang YL; Yang HB; Wu JJ
Dig Dis Sci; 2010 Jun; 55(6):1649-57. PubMed ID: 19690958
[TBL] [Abstract][Full Text] [Related]
5. Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients.
Gunes M; Kemik AS; Pirincci N; Gecit I; Taken K; Yuksel MB; Kaba M; Eryilmaz R
Asian Pac J Cancer Prev; 2013; 14(2):873-6. PubMed ID: 23621254
[TBL] [Abstract][Full Text] [Related]
6. Independent prognostic value of serum hepatocyte growth factor in bladder cancer.
Gohji K; Nomi M; Niitani Y; Kitazawa S; Fujii A; Katsuoka Y; Nakajima M
J Clin Oncol; 2000 Aug; 18(16):2963-71. PubMed ID: 10944129
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer.
Zhang J; Zhou X; Ding H; Wang L; Liu S; Liu Y; Chen Z
BMC Urol; 2020 Mar; 20(1):31. PubMed ID: 32192483
[TBL] [Abstract][Full Text] [Related]
8. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.
Andrews B; Shariat SF; Kim JH; Wheeler TM; Slawin KM; Lerner SP
J Urol; 2002 Mar; 167(3):1475-81. PubMed ID: 11832773
[TBL] [Abstract][Full Text] [Related]
9. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer.
Svatek RS; Shah JB; Xing J; Chang D; Lin J; McConkey DJ; Wu X; Dinney CP
Cancer; 2010 Oct; 116(19):4513-9. PubMed ID: 20572047
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
11. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer.
Szarvas T; László V; Vom Dorp F; Reis H; Szendröi A; Romics I; Tilki D; Rübben H; Ergün S
Int J Cancer; 2012 Jun; 130(12):2922-9. PubMed ID: 21815140
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder.
Guan KP; Ye HY; Yan Z; Wang Y; Hou SK
Urology; 2003 Apr; 61(4):719-23. PubMed ID: 12670552
[TBL] [Abstract][Full Text] [Related]
13. Prognostic-factors-based risk-stratification model for invasive urothelial carcinoma of the urinary bladder in Taiwan.
Yang MH; Yen CC; Chen PM; Wang WS; Chang YH; Huang WJ; Fan FS; Chiou TJ; Liu JH; Chen KK
Urology; 2002 Feb; 59(2):232-8; discussion 238-9. PubMed ID: 11834392
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer.
Puntoni M; Petrera M; Campora S; Garrone E; Defferrari C; Torrisi R; Johansson H; Bruno S; Curotto A; DeCensi A
Cancer Prev Res (Phila); 2016 Jun; 9(6):437-44. PubMed ID: 27045034
[TBL] [Abstract][Full Text] [Related]
15. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer.
Xue YJ; Lu Q; Sun ZX
Med Oncol; 2011 Dec; 28(4):1363-72. PubMed ID: 20509007
[TBL] [Abstract][Full Text] [Related]
16. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
17. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Jung K
Cancer Sci; 2008 Jun; 99(6):1188-94. PubMed ID: 18422740
[TBL] [Abstract][Full Text] [Related]
18. Serum Dickkopf-1 levels as a clinical and prognostic factor in patients with bladder cancer.
Sun DK; Wang L; Wang JM; Zhang P
Genet Mol Res; 2015 Dec; 14(4):18181-7. PubMed ID: 26782465
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
20. Circulating Anti-Matrix Metalloproteinase-7 Antibodies May Be a Potential Biomarker for Oral Squamous Cell Carcinoma.
Jiang T; Xie P; Liu H
J Oral Maxillofac Surg; 2016 Mar; 74(3):650-7. PubMed ID: 26454036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
